{"news_desk": "Business", "print_page": "5", "section_name": "Health", "subsection_name": null, "byline": {"original": "By SABRINA TAVERNISE", "person": [{"rank": 1, "role": "reported", "firstname": "Sabrina", "organization": "", "lastname": "TAVERNISE"}]}, "abstract": "Catalyst Pharmaceuticals, Florida firm in competition for approval of drug that treats rare neuromuscular disorder called Lambert-Eaton myasthenic syndrome, has setback when FDA says it requires more information before approval is granted.", "type_of_material": "News", "word_count": "287", "lead_paragraph": "Catalyst Pharmaceuticals, vying for exclusive rights to a drug that treats a rare neuromuscular condition, received a letter saying its application was incomplete.", "pub_date": "2016-02-18T00:00:00Z", "document_type": "article", "slideshow_credits": null, "headline": {"main": "F.D.A. Deals Setback to Catalyst in Race for Drug Approval", "print_headline": "Drug Maker Dealt Setback in Race for F.D.A. Assent"}, "snippet": "Catalyst Pharmaceuticals, vying for exclusive rights to a drug that treats a rare neuromuscular condition, received a letter saying its application was incomplete.", "multimedia": [], "web_url": "http://www.nytimes.com/2016/02/18/health/fda-deals-setback-to-catalyst-in-race-for-drug-approval.html", "keywords": [{"rank": "1", "is_major": "Y", "value": "Drugs (Pharmaceuticals)", "name": "subject"}, {"rank": "2", "is_major": "Y", "value": "Food and Drug Administration", "name": "organizations"}, {"rank": "3", "is_major": "Y", "value": "Catalyst Pharmaceutical Partners Inc", "name": "organizations"}, {"rank": "4", "is_major": "N", "value": "Muscular Dystrophy", "name": "subject"}, {"rank": "5", "is_major": "N", "value": "Prices (Fares, Fees and Rates)", "name": "subject"}, {"rank": "6", "is_major": "N", "value": "Jacobus Pharmaceutical Co", "name": "organizations"}], "blog": [], "_id": "56c4c1e038f0d85d2735f49d", "source": "The New York Times"}